Kyverna Therapeutics, Inc. Increase (Decrease) in Other Noncurrent Assets
Kyverna Therapeutics, Inc. (KYTX) reported Increase (Decrease) in Other Noncurrent Assets of -$1.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-11
- Kyverna Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was -$1.55M.
- Kyverna Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $5.00K, a 99.03% decline year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$483.00K, a 150.31% decline year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $958.00K, a 44.49% increase year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was $980.00K, a 49.87% decline from fiscal 2024.
- Kyverna Therapeutics, Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was $1.96M, a 5.73% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was $1.85M.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.54M 10-Q · filed 2026-08-11 | -$2.02M derived: sum of 3 quarters · filed 2026-08-11 | -$1.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $5.00K 10-Q · filed 2026-05-12 | -$478.00K derived: sum of 2 quarters · filed 2026-05-12 | $480.00K derived: sum of 3 quarters · filed 2026-05-12 | $470.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $475.00K derived: sum of 2 quarters · filed 2026-03-26 | $465.00K derived: sum of 3 quarters · filed 2026-08-11 | $980.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $958.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $948.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.46M 10-Q · filed 2025-11-12 | $2.42M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $505.00K 10-Q · filed 2026-08-11 | $1.47M derived: sum of 3 quarters · filed 2026-08-11 | $2.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $515.00K 10-Q · filed 2026-05-12 | $1.48M derived: sum of 2 quarters · filed 2026-05-12 | $2.14M derived: sum of 3 quarters · filed 2026-05-12 | $2.18M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.62M derived: sum of 2 quarters · filed 2026-03-26 | $1.66M derived: sum of 3 quarters · filed 2026-03-26 | $1.96M 10-K · filed 2026-03-26 |
| 2024-09-30 | $663.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $702.00K derived: sum of 2 quarters · filed 2025-11-12 | $995.00K 10-Q · filed 2025-11-12 | $2.81M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $332.00K 10-Q · filed 2025-08-12 | $2.14M derived: sum of 3 quarters · filed 2025-08-12 | $2.32M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $293.00K 10-Q · filed 2025-05-13 | $2.10M derived: sum of 2 quarters · filed 2025-05-13 | $2.28M derived: sum of 3 quarters · filed 2025-05-13 | $1.71M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.99M derived: sum of 2 quarters · filed 2025-03-27 | $1.41M derived: sum of 3 quarters · filed 2025-03-27 | $1.85M 10-K · filed 2025-03-27 |
| 2023-09-30 | $173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$398.00K derived: sum of 2 quarters · filed 2024-11-13 | $37.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$571.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$136.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $435.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |